Recombinant adeno-associated virus 2 (AAV) vectors transduction efficiency varies greatly in different cell types. We have described that a cellular protein, FKBP52, in its phosphorylated form interacts with the D-sequence in the viral inverted terminal repeat, inhibits viral second strand DNA synthesis, and limits transgene expression. Here we investigated the role of cellular heat-shock protein 90 (HSP90) in AAV transduction because FKBP52 forms a complex with HSP90, and because heat-shock treatment augments AAV transduction efficiency. Heat-shock treatment of HeLa cells resulted in tyrosine dephosphorylation of FKBP52, led to stabilization of the FKBP52-HSP90 complex, and resulted in ϳ6-fold increase in AAV transduction. However, when HeLa cells were pre-treated with tyrphostin 23, a specific inhibitor of cellular epidermal growth factor receptor tyrosine kinase, which phosphorylates FKBP52 at tyrosine residues, heat-shock treatment resulted in a further 18-fold increase in AAV transduction. HSP90 was shown to be a part of the FKBP52-AAV Dsequence complex, but HSP90 by itself did not bind to the D-sequence. Geldanamycin treatment, which disrupts the HSP90-FKBP52 complex, resulted in >22-fold increase in AAV transduction in heat-shock-treated cells compared with heat shock alone. Deliberate overexpression of the human HSP90 gene resulted in a significant decrease in AAV-mediated transduction in tyrphostin 23-treated cells, whereas down-modulation of HSP90 levels led to a decrease in HSP90-FKBP52-AAV D-sequence complex formation, resulting in a significant increase in AAV transduction following pre-treatment with tyrphostin 23. These studies suggest that the observed increase in AAV transduction efficiency following heat-shock treatment is unlikely to be mediated by HSP90 alone and that increased levels of HSP90, in the absence of heat shock, facilitate binding of FKBP52 to the AAV D-sequence, thereby leading to inhibition of AAV-mediated transgene expression. These studies have implications in the optimal use of recombinant AAV vectors in human gene therapy.
Adeno-associated virus (AAV),1 type 2, a non-pathogenic human parvovirus, has gained attention as a vector for gene transfer and gene therapy (1-25). Although recombinant AAV vectors are currently in use in phase I/II clinical trials for gene therapy of cystic fibrosis and hemophilia B (1,5,8,11,22), and have been shown to transduce a wide variety of cells and tissues in vitro and in vivo (2-4, 6, 7, 9, 10, 12-21, 23-25), their transduction efficiency varies widely in different cell types. We and others have undertaken systematic studies to delineate various steps in the life cycle of AAV, which include viral binding and entry (26 -28), intracellular trafficking (29 -35), nuclear transport (29, 30, 34 -37), and viral second strand DNA synthesis (38 -47). The viral second strand DNA synthesis has been described by two independent laboratories to be the ratelimiting step, which leads to inefficient transduction by AAV vectors (38, 39). We have reported that ...